Pfizer's GBS6 Vaccine Candidate Showcases Promising Protection for Infants Against Invasive GBS Disease: Phase 2 Study Reveals
Portfolio Pulse from Vandana Singh
Pfizer Inc has announced promising data from a Phase 2 study of its GBS6 vaccine candidate, developed to protect infants against invasive Group B Streptococcus (GBS) disease. The study enrolled 360 healthy pregnant individuals in South Africa, and the vaccine generated robust maternal antibody responses. The data suggests that GBS6 may offer meaningful protection against invasive GBS disease in newborns and young infants. Pfizer's shares are up 0.22% at $36.52 during the premarket session on the last check Thursday.
July 20, 2023 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's GBS6 vaccine candidate shows promising results in Phase 2 study, potentially offering protection for infants against invasive GBS disease. Pfizer's shares are up 0.22%.
The positive results from the Phase 2 study of Pfizer's GBS6 vaccine candidate are likely to boost investor confidence in the company's ability to develop effective vaccines, potentially leading to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100